Influenza Vaccines Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Description: Influenza Vaccines Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, “Influenza Vaccines Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global influenza vaccines market. The report identifies the key trends shaping and driving the global influenza vaccines market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global influenza vaccines sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData estimates that the global influenza vaccines market was valued at $3,525.1m in 2011, and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 5.8% over the next seven years, to reach $5,242.9m in 2018. The moderate growth of the market is due to the increasing awareness among people about the importance of vaccination against influenza vaccines, and the approval of new influenza vaccines vaccines. The universal immunization recommendation by the Advisory Committee on Immunization Practices (ACIP) and several government awareness vaccination programs would help to increase the vaccination coverage for influenza vaccines. The upcoming influenza vaccines vaccines include seasonal vaccines such as FluBlok and MEDI-3250, pandemic and pre-pandemic (mainly H5N1) vaccines such as Flu (Pre) Pandemic Vaccine, H5N1 pandemic influenza vaccines vaccine and Vepace, and universal influenza vaccines vaccines such as BVX-M001, MVA-NP+M1, Fluv-v and others. The influenza vaccines vaccines market is also set to witness the launch of quadrivalent vaccines such as Fluzone QIV, and adjuvant vaccines such as JVR-100 with Fluzone and IC31 Seasonal influenza vaccines Vaccine. The pipeline also includes vaccines with different routes of administration, such as oral vaccine (Avian influenza vaccines (H5N1) Oral Vaccine), nasal vaccine (influenza vaccines Intranasal Vaccine), vaccine in the form of nasal dry powder (GelVac), and vaccine patch (Pandemic influenza vaccines Vaccine Patch).

Scope

The report provides information on the key drivers and challenges of the influenza vaccines market. Its scope includes -
- Annualized seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan) influenza vaccines market revenues data from 2005 to 2010, forecast for eight years to 2018.
- Pipeline analysis data providing a split across the different phases, type of vaccines being developed and emerging trends by seven key markets. Pipeline candidates fall under major classes such as conjugate vaccine, combinational vaccine, polysachharide vaccines and others.
- Analysis of the current and future competition in the seven key countries influenza vaccines market. Key market players covered are Novartis AG, GlaxoSmithKline, Sanofi, Pfizer Inc, LG Life Sciences, Sinovac Biotech and Eurocrine Vaccines.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the influenza vaccines therapeutics market.
- Analysis of key recent licensing and partnership agreements in influenza vaccines market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global influenza vaccines market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global influenza vaccines market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What is the next big thing in the global influenza vaccines market landscape? – Identify, understand and capitalize.

Contents:

1
1.1 List of Tables
1.2 List of Figures
2 Influenza Vaccines - Introduction
2.1 Disease Overview
2.2 Epidemiology
2.3 Etiology and Pathophysiology
2.3.1 Types of Influenza Virus
2.3.2 Source of Influenza Virus
2.3.3 Drifting and Shifting of Influenza Virus
2.4 Signs and Symptoms
2.5 Diagnosis
2.6 Treatment and Management Options
2.7 GlobalData Pipeline Report Guidance
3 Influenza Vaccines: Market Characterization
3.1 Influenza Vaccines Market Size (2005-2010) – Global
3.2 Influenza Vaccines Market Forecast (2011-2018) – Global
3.3 Influenza Vaccines Market Size (2005-2010) – The US
3.5 Influenza Vaccines Market Size (2005-2010) – France
3.6 Influenza Vaccines Market Forecast (2011-2018) – France
3.7 Influenza Vaccines Market Size (2005-2010) – Germany
3.8 Influenza Vaccines Market Forecast (2011-2018) – Germany
3.9 Influenza Vaccines Market Size (2005-2010) – Italy
3.10 Influenza Vaccines Market Forecast (2011-2018) – Italy
3.11 Influenza Vaccines Market Size (2005-2010) – Spain
3.12 Influenza Vaccines Market Forecast (2011-2018) – Spain
3.13 Influenza Vaccines Market Size (2005-2010) – The UK
3.15 Influenza Vaccines Market Size (2005-2010) – Japan
3.16 Influenza Vaccines Market Forecast (2011-2018) – Japan
3.17 Drivers and Barriers for the Influenza Vaccines Market
3.17.1 Drivers for the Influenza Vaccines Market
3.17.2 Barriers for the Influenza Vaccines Market
3.18 Opportunity and Unmet Need Analysis
3.19 Key Takeaway
4 Influenza Vaccines: Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profiles for the Major Marketed Products in the Influenza Vaccines Market
4.3.1 Fluarix
4.3.2 FluLaval
4.3.3 Flumist
4.3.4 Fluvirin
4.3.5 Fluzone
4.4 Key Takeaway
5 Influenza Vaccines - Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.2.1 Influenza Vaccines Pipeline – Pipeline by Phases of Development
5.2.2 Influenza Vaccines – Regulatory Filed Products
5.2.3 Influenza Vaccines – Phase III Pipeline
5.2.4 Influenza Vaccines – Phase II Pipeline
5.2.5 Influenza Vaccines – Phase I Pipeline
5.2.6 Influenza Vaccines – Pre-Clinical Pipeline
5.2.7 Influenza Vaccines – Discovery Pipeline
5.2.8 Technology Trends Analytical Framework
5.3 Influenza Vaccines – Clinical Pipeline by Types of Vaccine
5.4 Influenza Vaccines – Promising Drugs Under Clinical Development
5.5 Molecule Profile for Promising Drugs Under Clinical Development
5.5.1 FluBlok
5.5.2 Flu Vaccine
5.5.3 MEDI 3250
5.5.4 A-04-01D Vaccine
5.5.5 H5N1 Pandemic Influenza Vaccine
5.5.6 Vepacel
5.6 Key Takeaway
6 Influenza Vaccines: Clinical Trials Mapping
6.1 Clinical Trials by Region/Country (The US, EUs and Japan)
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Prominent Sponsors
6.5 Top Companies Participating in Influenza Vaccines Clinical Trials
7 Influenza Vaccines: Strategic Assessment
7.1 Key Events Impacting the Future Market
7.2 Influenza Vaccines: Implications for Future Market Competition
8 Influenza Vaccines: Future Players
8.1 Introduction
8.2 Company Profiles
8.2.1 AstraZeneca PLC
8.2.2 GlaxoSmithKline plc
8.2.3 Novartis AG
8.2.4 Baxter International Inc.
9 Influenza Vaccines: Licensing and Partnership Deals
10 Influenza Vaccines: Appendix
10.1 Market Definitions
10.2 Abbreviations
10.3 Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography
1.1 List of Tables
Table 1: Influenza Vaccines Market, Global, Revenue ($m), 2005–2010
Table 2: Influenza Vaccines Market, Global, Forecast ($m), 2011–2018
Table 3: Influenza Vaccines Market, The US, Revenue ($m), 2005–2010
Table 4: Influenza Vaccines Market, The US, Forecasts ($m), 2011–2018
Table 5: Influenza Vaccines Market, France, Revenue ($m), 2005–2010
Table 6: Influenza Vaccines Market, France, Forecasts ($m), 2011–2018
Table 7: Influenza Vaccines Market, Germany, Revenue ($m), 2005–2010
Table 8: Influenza Vaccines Market, Germany, Forecasts ($m), 2011–2018
Table 9: Influenza Vaccines Market, Italy, Revenue ($m), 2005–2010
Table 10: Influenza Vaccines Market, Italy, Forecasts ($m), 2011–2018
Table 11: Influenza Vaccines Market, Spain, Revenue ($m), 2005–2010
Table 12: Influenza Vaccines Market, Spain, Forecasts ($m), 2011–2018
Table 13: Influenza Vaccines Market, The UK, Revenue ($m), 2005–2010
Table 14: Influenza Vaccines Market, The UK, Forecasts ($m), 2011–2018
Table 15: Influenza Vaccines Market, Japan, Revenue ($m), 2005–2010
Table 16: Influenza Vaccines Market, Japan, Forecasts ($m), 2011–2018
Table 17: Influenza Vaccines – Regulatory Filed Products, 2011
Table 18: Influenza Vaccines – Phase III Pipeline, 2011
Table 19: Influenza Vaccines – Phase II Pipeline, 2011
Table 20: Influenza Vaccines – Phase I Pipeline, 2011
Table 21: Influenza Vaccines – Pre-Clinical Pipeline, 2011
Table 22: Influenza Vaccines – Discovery Pipeline, 2011
Table 23: Influenza Vaccines – Most Promising Drugs Under Clinical Development, 2011
Table 24: Influenza Vaccines – Clinical Trials by Country, 2011
Table 25: Influenza Vaccines – Clinical Trials by Phase, 2011
Table 26: Influenza Vaccines – Clinical Trials by Status, 2011
Table 27: Influenza Vaccines – Overall Sponsors, 2011
Table 28: Influenza Vaccines – Prominent Sponsors, 2011
Table 29: Influenza Vaccines – Top Companies Participating in Clinical Trials, 2011
Table 30: Astrazeneca - Influenza Pipeline Products, 2011
Table 31: GlaxoSmithKline - Influenza Pipeline Products, 2011
Table 32: Novartis AG - Influenza Pipeline Products, 2011
Table 33: Baxter International - Influenza Pipeline Products, 2011
Table 34: Influenza Vaccines: Licensing and Partnership Deals, 2011

1.2 List of Figures
Figure 1: Comparison of Seasonal and Pandemic Influenza
Figure 2: Comparison of Influenza A, B and C
Figure 3: Comparison of Influenza and the Common Cold
Figure 4: Influenza Virus Testing Methods
Figure 5: Clinical Algorithm for Consideration in the Assessment of Persons with Mild or Uncomplicated Influenza Illness
Figure 6: Influenza Vaccines Market, Global, Revenue ($m), 2005–2010
Figure 7: Influenza Vaccines Market, Global, Forecast ($m), 2011–2018
Figure 8: Influenza Vaccines Market, The US, Revenue ($m), 2005–2010
Figure 9: Influenza Vaccines Market, The US, Forecast ($m), 2011–2018
Figure 10: Influenza Vaccines Market, France, Revenue ($m), 2005–2010
Figure 11: Influenza Vaccines Market, France, Forecast ($m), 2011–2018
Figure 12: Influenza Vaccines Market, Germany, Revenue ($m), 2005–2010
Figure 13: Influenza Vaccines Market, Germany, Forecast ($m), 2011–2018
Figure 14: Influenza Vaccines Market, Italy, Revenue ($m), 2005–2010
Figure 15: Influenza Vaccines Market, Italy, Forecast ($m), 2011–2018
Figure 16: Influenza Vaccines Market, Spain, Revenue ($m), 2005–2010
Figure 17: Influenza Vaccines Market, Spain, Forecast ($m), 2011–2018
Figure 18: Influenza Vaccines Market, The UK, Revenue ($m), 2005–2010
Figure 19: Influenza Vaccines Market, The UK, Forecast ($m), 2011–2018
Figure 20: Influenza Vaccines Market, Japan, Revenue ($m), 2005–2010
Figure 21: Influenza Vaccines Market, Japan, Forecast ($m), 2011–2018
Figure 22: Opportunity and Unmet Need in the Influenza Vaccines Market
Figure 23: Influenza Vaccines – Strategic Competitor Assessment, 2010
Figure 24: Influenza Vaccines – Pipeline by Phase of Development, 2011
Figure 25: Influenza Vaccines – Technology Trends Analytics Framework, 2011
Figure 26: Influenza Vaccines – Technology Trends Analytics Framework – Description, 2011
Figure 27: Influenza Vaccines – Pipeline by Types of Vaccines, 2011
Figure 28: Influenza Vaccines – Clinical Trials by Country, 2011
Figure 29: Influenza Vaccines – Clinical Trials by Phase, 2011
Figure 30: Influenza Vaccines – Clinical Trials by Status, 2011
Figure 31: Influenza Vaccines – Overall Sponsors, 2011
Figure 32: Influenza Vaccines – Prominent Sponsors, 2011
Figure 33: Influenza Vaccines – Top Companies Participating in Clinical Trials, 2011
Figure 34: Influenza Vaccines Market, Drivers and Barriers, 2011
Figure 35: Implications for Future Market Competition in the Influenza Vaccines Market, 2011
Figure 36: Influenza Vaccines Market – Pipeline by Company, 2011
Figure 37: GlobalData Market Forecasting Model

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Influenza Vaccines Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Web Address: http://www.researchandmarkets.com/reports/1936740/
Office Code: SC6IYJ9L

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Product Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td></td>
<td>USD 3500</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td></td>
<td>USD 7000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td></td>
<td>USD 10500</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr  Mrs  Dr  Miss  Ms  Prof
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: _______________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World